Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease.

Journal of Neural Transmission
Robert A RissmanPaul S Aisen

Abstract

Alzheimer's disease (AD) affects more than twenty-five million people worldwide and is the most common form of dementia. Symptomatic treatments have been developed, but effective intervention to alter disease progression is needed. Targets have been identified for disease-modifying drugs, but the results of clinical trials have been disappointing. Peripheral biomarkers of disease state may improve clinical trial design and analysis, increasing the likelihood of successful drug development. Amyloid-related measures, presumably reflecting principal pathology of AD, are among the leading cerebrospinal fluid and neuroimaging biomarkers, and measurement of plasma levels of amyloid peptides has been the focus of much investigation. In this review, we discuss recent data on plasma β-amyloid (Aβ) and examine the issues that have arisen in establishing it as a reliable biomarker of AD.

References

Jan 1, 1994·Annual Review of Neuroscience·D J Selkoe
Dec 20, 1996·The Journal of Biological Chemistry·A L BiereD J Selkoe
Apr 17, 1998·Clinica Chimica Acta; International Journal of Clinical Chemistry·A R KoudinovN V Koudinova
Oct 28, 1998·Journal of Physiology, Paris·S G Younkin
Sep 11, 1999·Annals of Neurology·R MayeuxP D Mehta
Sep 10, 2002·Alzheimer Disease and Associated Disorders·Zoe ArvanitakisNeill R Graff-Radford
Jul 23, 2003·Archives of Neurology·Hiroaki FukumotoMichael C Irizarry
Aug 5, 2003·The Journal of Clinical Investigation·John R Cirrito, David M Holtzman
Dec 16, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Fiona M LairdPhilip C Wong
Dec 17, 2005·Journal of Applied Physiology·Helene Girouard, Costantino Iadecola
Jul 22, 2006·Lancet Neurology·Marieke van OijenMonique M B Breteler
Jun 7, 2007·Proceedings of the National Academy of Sciences of the United States of America·Jae-Eun KangDavid M Holtzman
Oct 5, 2007·Neurology·N Ertekin-TanerN R Graff-Radford
Oct 16, 2007·Neuroscience Letters·Vilmantas GiedraitisLars Lannfelt
Sep 10, 2008·Proceedings of the National Academy of Sciences of the United States of America·Nicole SchupfRichard Mayeux
Feb 18, 2009·Journal of Alzheimer's Disease : JAD·Sara F HanssonKaj Blennow
May 20, 2009·Biochemical and Biophysical Research Communications·Shuko TakedaRyuichi Morishita
Jul 3, 2009·Alzheimer Disease and Associated Disorders·Yasuji MatsuokaPaul S Aisen
Oct 14, 2009·Archives of Neurology·Olivia I OkerekeFrancine Grodstein
Oct 30, 2009·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Alex E RoherThomas G Beach
Dec 7, 2010·Progress in Neurobiology·Harald HampelUNKNOWN Oxford Task Force Group
Jan 20, 2011·JAMA : the Journal of the American Medical Association·Kristine YaffeTamara B Harris
Jul 26, 2011·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Niklas MattssonKaj Blennow
Aug 2, 2011·Acta Neuropathologica·Jon B ToledoUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Oct 1, 2011·Neurobiology of Aging·Antonia M W CoppusCornelia M van Duijn

❮ Previous
Next ❯

Citations

Mar 9, 2013·Alzheimer's Research & Therapy·Jon B ToledoJohn Q Trojanowski
Aug 25, 2012·Biomarkers in Medicine·Chantal Bazenet, Simon Lovestone
Jul 15, 2015·Expert Review of Proteomics·Sara GalozziKatalin Barkovits
Oct 11, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Michael C DonohueRobert A Rissman
Jun 16, 2015·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Michael W WeinerUNKNOWN Alzheimer's Disease Neuroimaging Initiative
May 31, 2016·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Cassandra A DeMarshallUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Jul 16, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Kim HenriksenUNKNOWN Blood-Based Biomarker Interest Group
Sep 14, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Vincent ChourakiSudha Seshadri
Sep 28, 2013·Biochimica Et Biophysica Acta·Russell H SwerdlowShaharyar M Khan
Jul 22, 2015·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Ju-Hee KangUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Apr 1, 2014·Brain Structure & Function·Gabriel Gonzalez-EscamillaJose L Cantero
Aug 13, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Michael W WeinerUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Nov 29, 2015·Journal of Thrombosis and Haemostasis : JTH·D ZamolodchikovS Strickland
Oct 13, 2017·International Journal of Molecular Sciences·Ciro De LucaMichele Papa
Nov 14, 2014·Proceedings of the Japan Academy. Series B, Physical and Biological Sciences·Naoki KanekoKatsuhiko Yanagisawa
Jul 1, 2019·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Oscar L LopezLewis H Kuller
Jun 2, 2016·Oncotarget·Lu YangYuesheng Zhang
Feb 22, 2018·Oncotarget·Lu YangYuesheng Zhang
Dec 1, 2016·Dementia and Neurocognitive Disorders·Ho Sik ShinSun Ah Park
Apr 11, 2019·International Journal of Molecular Sciences·Seongju LeeJu-Hee Kang
Jan 31, 2020·Brain Communications·Oscar L LopezLewis H Kuller
Jul 25, 2018·Journal of Alzheimer's Disease : JAD·Sebastian AguayoLuis Gerardo Aguayo
Aug 28, 2020·Frontiers in Cell and Developmental Biology·Yuan-Han YangLi-Ju Huang
Jan 30, 2020·Computer Methods and Programs in Biomedicine·Gerard Martí-JuanGemma Piella
Jan 29, 2020·Dementia and Geriatric Cognitive Disorders·Ting-Bin ChenIrene H Cheng

❮ Previous
Next ❯

Related Concepts

Related Feeds

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.